News
MEDP
569.98
+0.43%
2.42
Weekly Report: what happened at MEDP last week (1222-1226)?
Weekly Report · 20h ago
Medpace (MEDP): Assessing Valuation After a Strong Multi‑Year Share Price Run
Simply Wall St · 5d ago
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
NASDAQ · 5d ago
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
NASDAQ · 6d ago
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD
Seeking Alpha · 12/23 05:06
Here's Why You Should Retain INSP Stock in Your Portfolio Now
NASDAQ · 12/22 12:51
Weekly Report: what happened at MEDP last week (1215-1219)?
Weekly Report · 12/22 09:41
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
NASDAQ · 12/19 23:15
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
NASDAQ · 12/19 15:25
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
NASDAQ · 12/19 13:41
ECL Boosts High-Tech Water Platform With Ovivo's Electronics Business
NASDAQ · 12/18 16:00
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
NASDAQ · 12/18 14:07
Here's Why You Should Retain CLOV Stock in Your Portfolio Now
NASDAQ · 12/18 13:28
GEHC Expands Healthcare Access Through Indonesia MoH Partnership Deal
NASDAQ · 12/17 17:02
Medpace Holdings Price Target Raised to $525.00/Share From $485.00 by Barclays
Dow Jones · 12/15 21:13
Medpace Holdings Is Maintained at Underweight by Barclays
Dow Jones · 12/15 21:13
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $525
Benzinga · 12/15 21:03
BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
NASDAQ · 12/15 15:24
MEDPACE HOLDINGS INC <MEDP.O>: BARCLAYS RAISES TARGET PRICE TO $525 FROM $485
Reuters · 12/15 11:08
Medpace price target raised to $525 from $485 at Barclays
TipRanks · 12/15 11:01
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.